Clinical Trial Update: FOLFIRI or FOLFOX With or Without Cetuximab in Patients With Metastatic Adenocarcinoma of the Colon or Rectum [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating FOLFIRI or FOLFOX with or without cetuximab in metastatic colorectal cancer was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Cetuximab (cetuximab)
• FOLFIRI (irinotecan, leucovorin, 5-fluorouracil)
• FOLFOX

Snippet

Sponsor: Alliance for Clinical Trials in Oncology | Conditions: Colorectal Cancer | Phase 3 | Status: TERMINATED